Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

RT @LiquidLifeBC: In the search for a therapeutic to address treatment-resistant depression, #psilocybin (magic mushrooms) may prove to be…

RT @LiquidLifeBC: In the search for a therapeutic to address treatment-resistant depression, #psilocybin (magic mushrooms) may prove to be…

In the search for a therapeutic to address treatment-resistant depression, #psilocybin (magic mushrooms) may prove to be a viable solution. In the following study, psilocybin reduced depression, anxiety and anhedonia. 🍄 https://t.co/gYdiBcqZk0

@jaxelinha @balloccoo https://t.co/XcsJPZY5PA

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

Full-text pdf: https://t.co/l1BKWdajCx @TheDailyShroom https://t.co/CqOGRHusFC

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

🗣🗣🗣🗣🗣@HighlyOptimize

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

#psilocybin #research on treatment-resistant #depression study As we survive and cope during this inevitable economic recession, it’s imperative that these natural alternatives become accessible for healing depression and trauma. Personal use should be de

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

Right on Doc @drmikehart ! #TogetherWeWILL https://t.co/ndwQgSgInZ xx

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

RT @drmikehart: 12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms)…

12 patients (six men and women) with treatment-resistant depression received 10mg and 25mg of psilocybin (magic mushrooms) 7 days apart in a supportive setting. Depression and anxiety scores were markedly reduced at 1 week and on a 3-month follow-up. h

@hazelinha Hay muchos reportes en la comunidad científica al respecto. https://t.co/3t8hluFnA1

@AliakbarAbolha1 @Sina_Thr https://t.co/WRBAWmyniQ

Psilocybin CAN help depression. https://t.co/M9Ipdq8fJs

@SnippyLady @Miles_Tarbox @caravsx Miles point is certainly valid. See https://t.co/UhEHE7qrvJ. In fairness, one must consider with a critical mindset. It's promising but no panacea. Nothing is with mental illness.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - ScienceDirect https://t.co/z4efIxjd2t

@joarhalvorsen @H_Grostad 1. Personer med behandlings-resistent depresjon viser en tydelig forbedring etter inntak av psilocybin i en terapeutisk kontekst. https://t.co/oANcaeHw3U

@MJA_Editor 1st ep covers psilocybin (magic mushrooms), Open-label study with people whose depression had failed to respond to standard treatments showed some improvements ...more research needed but a topic worthy of investigation? disclaimer i haven't se

RT @pharmacoeeg: Open-Label Trial showing Efficiancy of Psylocibin in the Treatment of Depression: https://t.co/H7xdEtH6Ea and https://t.co…

@andreas_wahl @dagfinnhessenp " Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference –11·8, 95% CI –9·15 to –14·35, p=0·002, Hedges’ g=3·1) and 3 months (–9·2, 95% CI –5·69 to –12·71, p=0·003, Hedges’ g=2) after high

https://t.co/CJn1zp4E5a

RT @emigrl: ランセットのマジックマッシュルームを使った鬱病治療の報告これね https://t.co/zGUcDzhbtB まだまだ研究が必要だけど、期待ができる。

RT @m_wall: @AllenFrancesMD @neuroraf Perhaps you'd consider trying psychedelic-assisted psychotherapy first? Very effective (early days fo…

@AllenFrancesMD @neuroraf Perhaps you'd consider trying psychedelic-assisted psychotherapy first? Very effective (early days for trials, but it's hopeful) and less invasive/fewer side effects. https://t.co/XSbNiY5SIy

@Okiedokie02 https://t.co/UexIPS4v3G

Psilocybin with psychological support for treatment-resistant depressi... https://t.co/UexIPS4v3G

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study https://t.co/8slH3An63y @TessTsindos #Sphpm

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

@MAPSCanada @RCarhartHarris @ProfDavidNutt @MendelKaelen Full-text pdf: https://t.co/nb2IXtnOU4 @Chacruna_net @hellopsillow @APRA_bot @BeckleyResearch

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

#Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility, safety & efficacy in patients with treatment-resistant depression. #BeckleyImperial @RCarhartHarris @ProfDavidNutt @MendelKaelen

Eens ✅ Maar... wél onder begeleiding, en niet voor de meute!

@strvrw @Merlijn65761540 @Vera_Bergkamp Drugs kunnen best geschikt zijn voor mensen. Zie bijv. https://t.co/1M0SIECroU, https://t.co/NIgrnuckGf, en https://t.co/uCMMN45apA. Onderzoek wordt zwaar belemmerd door de juridische status, ondanks veelbelovendheid

Psilocybin with psychological support for treatment-resistant depressi... https://t.co/Nbn1NJZ5eV

Researchers suggest removing schedule 1 classification for Psilocybin #Magic #mushroom https://t.co/WobeJBjJJh Quick pub med shows potential for: #treatment resistant #depression #PTSD #OCD #scicomm https://t.co/vNMZWtO39Z https://t.co/drUG5pQNQg http

@drkeithscott John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick pub med shows potential for: #treatment resistant #depression #PTSD #OCD #scicomm https://t.co/vNMZWtO39Z https://t.co/

@AOC Thank you @AOC Psilocybin with psychological support for treatment-resistant depressi... https://t.co/IiIVdIy4bc

Sounds radical and I can imagine it feeding into culture warring but it's just eminently sensible policy, with further research more than supported by the evidence (e.g. https://t.co/gWbORzId4A; https://t.co/4pErdYOeRq; https://t.co/gn71Fr2NLU)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study https://t.co/htBd5IS1Rn

@pinkyrosin https://t.co/9c7s7rwKDb

The open access Lancet Psych article is here: https://t.co/20Sf7Hbspb

@AntLiveOfficial @TheLSDBlotter So much research going on. I was at a talk by ketamine researchers a few weeks ago; they are doing therapy and research and about to release a second book about it. This research from 2016 on psilocybin & depression is r

Cogumelos psicodélicos apresentam ótimos resultados contra sintomas de depressão. ❤️🍄 #psychedelic #freelula #mariellefranco #depression https://t.co/yh5f7HunZ0

RT @NicholasJohn83: John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick…

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @NicholasJohn83: John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick…

John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick pub med shows potential for: #treatment resistant #depression #PTSD #OCD #scicomm https://t.co/vNMZWtO39Z https://t.co/drUG5pQNQg ht

RT @annatessrickman: @CharlesFLehman @LeoBeletsky @RCarhartHarris @TEDx https://t.co/ui78zPgNwB

RT @DayanaHappyBody: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet…

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @DayanaHappyBody: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet…

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

寛解って事は摂取し続けなければならないのか？

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psychiatry ⁦@tferriss⁩ https://t.co/4ef3MBrbMc

@CharlesFLehman @LeoBeletsky @RCarhartHarris @TEDx https://t.co/ui78zPgNwB

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psychiatry https://t.co/CAJKPpg8kd

RT @KyYaYa1970: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psyc…

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psychiatry. ScienceDirect https://t.co/4KTevjhQHk

Psilocybiiniä testattiin laajempaa kliinistä tutkimusta varten. 12 depressiosta kärsivästä osanottajasta psilocybiini näytti tehoa 1 viikko hoidon jälkeen, ja suurin osa 3kk hoidosta. https://t.co/CfPc47Q1wU

RT @PrivilegeHealth: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. https://t.c…

RT @PrivilegeHealth: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. https://t.c…